1. Bindraban, R.S., et al., Reducing Test Utilization in Hospital Settings: A Narrative Review. Ann Lab Med, 2018. 38(5): p. 402–12.
2. Hauser, R.G. and B.H. Shirts, Do we now know what inappropriate laboratory utilization is? An expanded systematic review of laboratory clinical audits. Am J Clin Pathol, 2014. 141(6): p. 774–83.
3. Zhi, M., et al., The Landscape of Inappropriate Laboratory Testing: A 15-Year Meta-Analysis. PLOS ONE, 2013. 8(11): p. e78962.
4. Smoller, B.R. and M.S. Kruskall, Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med, 1986. 314(19): p. 1233–5.
5. Stuebing, E.A. and T.J. Miner, Surgical vampires and rising health care expenditure: reducing the cost of daily phlebotomy. Arch Surg, 2011. 146(5): p. 524–7.
6. Thavendiranathan, P., et al., Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med, 2005. 20(6): p. 520–4.
7. Salisbury, A.C., et al., Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med, 2011. 171(18): p. 1646–53.
8. Cassel, C.K. and J.A. Guest, Choosing wisely: helping physicians and patients make smart decisions about their care. Jama, 2012. 307(17): p. 1801–2.
9. Valencia, V., et al., A Comparison of Laboratory Testing in Teaching vs Nonteaching Hospitals for 2 Common Medical Conditions. JAMA Intern Med, 2018. 178(1): p. 39–47.
10. Feely, M.A., et al., Preoperative testing before noncardiac surgery: guidelines and recommendations. Am Fam Physician, 2013. 87(6): p. 414–8.
11. Kirkham, K.R., et al., Preoperative Laboratory Investigations: Rates and Variability Prior to Low-risk Surgical Procedures. Anesthesiology, 2016. 124(4): p. 804–14.
12. Kirkham, K.R., et al., Preoperative testing before low-risk surgical procedures. Cmaj, 2015. 187(11): p. E349–58.
13. Rolfe, A. and C. Burton, Reassurance after diagnostic testing with a low pretest probability of serious disease: systematic review and meta-analysis. JAMA Intern Med, 2013. 173(6): p. 407–16.
14. Stevens, S.M., et al., Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016. 41(1): p. 154–64.
15. Rusk, M.H., Avoiding Unnecessary Preoperative Testing. Med Clin North Am, 2016. 100(5): p. 1003–8.
16. Stevens, D.L., et al., Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2014. 59(2): p. e10-e52.
17. Ellenbogen, M.I., et al., Differences in Routine Laboratory Ordering Between a Teaching Service and a Hospitalist Service at a Single Academic Medical Center. South Med J, 2017. 110(1): p. 25–30.
18. Konger, R.L., et al., Reduction in Unnecessary Clinical Laboratory Testing Through Utilization Management at a US Government Veterans Affairs Hospital. Am J Clin Pathol, 2016. 145(3): p. 355–64.
19. Melendez-Rosado, J., et al., Reducing unnecessary testing: an intervention to improve resident ordering practices. Postgrad Med J, 2017. 93(1102): p. 476–9.
20. Baird, G., The laboratory test utilization management toolbox. Biochemia Medica, 2014. 24(2): p. 223–34.
21. Kennedy, M., et al., Do emergency department blood cultures change practice in patients with pneumonia? Ann Emerg Med, 2005. 46(5): p. 393–400.
22. Makam, A.N., A.D. Auerbach, and M.A. Steinman, Blood culture use in the emergency department in patients hospitalized for community-acquired pneumonia. JAMA Intern Med, 2014. 174(5): p. 803–6.
23. Mountain, D., et al., Blood cultures ordered in the adult emergency department are rarely useful. Eur J Emerg Med, 2006. 13(2): p. 76–9.
24. Towns, M.L., W.R. Jarvis, and P.R. Hsueh, Guidelines on blood cultures. J Microbiol Immunol Infect, 2010. 43(4): p. 347–9.
25. Hall, K.K. and J.A. Lyman, Updated Review of Blood Culture Contamination. Clinical Microbiology Reviews, 2006. 19(4): p. 788–802.
26. Coburn, B., et al., Does this adult patient with suspected bacteremia require blood cultures? Jama, 2012. 308(5): p. 502–11.
27. Roth, A., et al., Reducing blood culture contamination by a simple informational intervention. J Clin Microbiol, 2010. 48(12): p. 4552–8.
28. Mandell, L.A., et al., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases, 2007. 44(Supplement_2): p. S27–S72.
29. Jessen, M.K., et al., Prediction of bacteremia in the emergency department: an external validation of a clinical decision rule. Eur J Emerg Med, 2016. 23(1): p. 44–9.
30. Shapiro, N.I., et al., Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med, 2008. 35(3): p. 255–64.
31. Jones, G.R. and J.A. Lowes, The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. Qjm, 1996. 89(7): p. 515–22.
32. Woodhead, M., et al., Guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal, 2005. 26(6): p. 1138–1180.
33. Laifer, G., et al., Management of Community Acquired Pneumonia (CAP) in Adults (ERS/ESCMID guidelines1 adapted for Switzerland). 2002.
34. Leth, R.A., B.E. Forman, and B. Kristensen, Predicting bloodstream infection via systemic inflammatory response syndrome or biochemistry. J Emerg Med, 2013. 44(2): p. 550–7.
35. Bates, D.W., L. Goldman, and T.H. Lee, Contaminant blood cultures and resource utilization. The true consequences of false-positive results. Jama, 1991. 265(3): p. 365–9.
36. Bruns, A.H., et al., Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J, 2008. 32(3): p. 726–32.
37. Coelho, L., et al., Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care, 2007. 11(4): p. R92.
38. Povoa, P., A.M. Teixeira-Pinto, and A.H. Carneiro, C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care, 2011. 15(4): p. R169.
39. Moreno, M.S., et al., C-reactive protein: a tool in the follow-up of nosocomial pneumonia. J Infect, 2010. 61(3): p. 205–11.
40. Schmit, X. and J.L. Vincent, The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection, 2008. 36(3): p. 213–9.
41. Povoa, P., et al., Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis, 2005. 40(12): p. 1855–7.
42. Lobo, S.M., Sequential C-reactive protein measurements in patients with serious infections: does it help? Crit Care, 2012. 16(3): p. 130.
43. Nicolle, L.E., Urinary tract infection in geriatric and institutionalized patients. Curr Opin Urol, 2002. 12(1): p. 51–5.
44. Boscia, J.A., et al., Lack of association between bacteriuria and symptoms in the elderly. Am J Med, 1986. 81(6): p. 979–82.
45. High, K.P., et al., Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis, 2009. 48(2): p. 149–71.
46. Bent, S., et al., Does this woman have an acute uncomplicated urinary tract infection? Jama, 2002. 287(20): p. 2701–10.
47. Midthun, S.J., R. Paur, and G. Lindseth, Urinary tract infections. Does the smell really tell? J Gerontol Nurs, 2004. 30(6): p. 4–9.
48. Bauer, T.M., et al., Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. Jama, 2001. 285(3): p. 313–9.
49. Seyler, L., et al., Safety and cost savings of an improved three-day rule for stool culture in hospitalised children and adults. J Hosp Infect, 2007. 67(2): p. 121–6.
50. Kobayashi, M., et al., Validation of the 3-day rule for stool bacterial tests in Japan. Intern Med, 2014. 53(6): p. 533–9.
51. Eggers, K.M., et al., Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J, 2004. 148(4): p. 574–81.
52. Saenger, A.K. and A.S. Jaffe, Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation, 2008. 118(21): p. 2200–6.
53. Thygesen, K., et al., Universal definition of myocardial infarction. Circulation, 2007. 116(22): p. 2634–53.
54. Kavsak, P.A., et al., Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta, 2007. 380(1–2): p. 213–6.
55. Reichlin, T., et al., Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med, 2009. 361(9): p. 858–67.
56. Barbieri, J.S., J.M. Riggio, and R. Jaffe, Amylase testing for abdominal pain and suspected acute pancreatitis. J Hosp Med, 2016. 11(5): p. 366–8.
57. Basnayake, C. and D. Ratnam, Blood tests for acute pancreatitis. Aust Prescr, 2015. 38(4): p. 128–30.
58. Lankisch, P.G., S. Burchard-Reckert, and D. Lehnick, Underestimation of acute pancreatitis: patients with only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Gut, 1999. 44(4): p. 542–4.
59. Smith, R.C., J. Southwell-Keely, and D. Chesher, Should serum pancreatic lipase replace serum amylase as a biomarker of acute pancreatitis? ANZ J Surg, 2005. 75(6): p. 399–404.
60. Viel, J.F., et al., Combined diagnostic value of biochemical markers in acute pancreatitis. Clin Chim Acta, 1990. 189(2): p. 191–8.
61. Yadav, D., N. Agarwal, and C.S. Pitchumoni, A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol, 2002. 97(6): p. 1309–18.
62. Vilstrup, H., et al., Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 2014. 60(2): p. 715–35.
63. Lockwood, A.H., Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis, 2004. 19(3–4): p. 345–9.
64. Tozzoli, R., et al., Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol, 2002. 117(2): p. 316–24.
65. Arnold, D.F., et al., Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J Clin Pathol, 2010. 63(8): p. 678–80.
66. Bush, T.M., T.L. Shlotzhauer, and W. Grove, Serum complements. Inappropriate use in patients with suspected rheumatic disease. Arch Intern Med, 1993. 153(20): p. 2363–6.
67. Lane, S.K. and J.W. Gravel, Jr., Clinical utility of common serum rheumatologic tests. Am Fam Physician, 2002. 65(6): p. 1073–80.
68. Kavanaugh, A., et al., Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med, 2000. 124(1): p. 71–81.
69. Agmon-Levin, N., et al., International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis, 2014. 73(1): p. 17–23.
70. Bossuyt, X., et al., Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol, 2017. 13(11): p. 683–92.
71. Hagen, E.C., et al., Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int, 1998. 53(3): p. 743–53.
72. Savige, J., et al., International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). American Journal of Clinical Pathology, 1999. 111(4): p. 507–13.
73. Miller, A., et al., Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. Rheumatology (Oxford), 2015. 54(10): p. 1882–9.
74. Shmerling, R.H. and T.L. Delbanco, How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value. Arch Intern Med, 1992. 152(12): p. 2417–20.
75. Nishimura, K., et al., Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med, 2007. 146(11): p. 797–808.
76. Clifford, B.D., et al., High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology, 1995. 21(3): p. 613–9.
77. Kobak, S., et al., Sarcoidois: is it only a mimicker of primary rheumatic disease? A single center experience. Ther Adv Musculoskelet Dis, 2014. 6(1): p. 3–7.
78. Hsu, F.C., et al., Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol, 2003. 30(3): p. 455–8.
79. Aletaha, D., et al., 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010. 62(9): p. 2569–81.